Bionik Laboratories Corp.

Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. Its products include InMotion ARM, InMotion HAND, and InMotion WRIST. The company was founded by Michal Prywata and Thiago Caires on January 8, 2010 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. It operates through the Rehabilitation Products and Service Business, and Rehabilitation Clinics segments. The company was founded by Michal Prywata and Thiago Caires on January 8, 2010 and is headquartered in Watertown, MA.

TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its first quarter of fiscal year 2022, for the period ended June 30, 2021. “The growing revenue trend that we had in the last quarter of fiscal 2021 continues into the first quarter of fiscal 2022. Our commercial pipe

BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results

TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, announced today it has entered into a series of agreements to issue secured convertible promissory notes of the Company (the “Loan”) for a total of $5 million in gross proceeds to the Company. Of the $5 million, 80% comes from new investors, highlighting

BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes

TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today has announced that Chief Executive Officer and Board Member Dr. Eric Dusseux has resigned as Chief Executive Officer and stepped down from the board, to pursue an opportunity outside the rehabilitation robotic device industry. The resignation is ef

BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO

TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its fourth quarter and fiscal year 2021, for the periods ended March 31, 2021. “We are starting to see an uptick in commercial sales as we put fiscal 2021 behind us. The fourth quarter was our strongest quarter for fi

BIONIK Laboratories Reports Fiscal 2021 Financial Results

News for Bionik Laboratories Corp. Stock (BNKL)